Reaffirms Full Year 2021 Earnings Guidance
|
Quarter ended |
|
Nine months ended |
||||
|
|
|
|
||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
|
|
|
|
|
|
|
|
|
(In millions, except per-share results) |
||||||
Premium Revenue |
|
|
|
|
|
|
|
Total Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP: |
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
EPS – Diluted |
|
|
|
|
|
|
|
Medical Care Ratio (MCR) |
88.9% |
|
85.9% |
|
88.1% |
|
84.9% |
G&A Ratio |
7.5% |
|
7.3% |
|
7.3% |
|
7.3% |
After-tax Margin |
2.0% |
|
3.7% |
|
2.7% |
|
4.5% |
|
|
|
|
|
|
|
|
Adjusted: |
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
EPS – Diluted |
|
|
|
|
|
|
|
G&A Ratio |
7.3% |
|
7.3% |
|
7.1% |
|
7.2% |
After-tax Margin |
2.3% |
|
4.0% |
|
3.1% |
|
4.7% |
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release. |
|||||||
Quarter Highlights
-
GAAP net income for the third quarter of 2021 was
$143 million , or$2.46 per diluted share. -
Adjusted net income for the third quarter of 2021 was
$164 million , or$2.83 per diluted share. -
As of
September 30, 2021 , the Company served approximately 4.8 million members, an increase of 805,000 members, or 20%, compared toSeptember 30, 2020 . -
Premium revenue was approximately
$6.8 billion for the third quarter of 2021, an increase of 43% compared to the third quarter of 2020. -
The net effect of COVID decreased net income by approximately
$1.00 per diluted share in the third quarter of 2021. -
The Company increased its full year 2021 premium revenue guidance to no less than
$26.5 billion . -
The Company reaffirmed its full year 2021 adjusted earnings guidance of no less than
$13.25 per diluted share.
“We are pleased with our third quarter and year-to-date performance. With the backdrop of a continuing pandemic, we executed well, delivered solid operating earnings, and continued to drive our growth strategy,” said
New York Acquisitions
On
On
Premium Revenue
Premium revenue was approximately
Net Income
Net income for the third quarter was
The year-over-year comparison reflects the negative impact from the net effect of COVID in the third quarter of 2021. In contrast, the prior year third quarter was positively impacted by the net effect of COVID.
Net income for the nine months ended
Medical Care Ratio
The consolidated MCR for the third quarter was 88.9%, compared to 85.9% in the third quarter of 2020. The net effect of COVID increased the consolidated MCR by approximately 110 basis points and impacted all three lines of business. In the prior year, the net effect of COVID was negligible to slightly positive.
A year-over-year comparison is less meaningful than it would be in a typical year due to pandemic related effects. Due to those anomalous effects, a sequential comparison of MCR is more relevant.
On a sequential basis, the consolidated MCR for the third quarter was 88.9%, compared to 88.4% in the second quarter of 2021. The net effect of COVID increased the consolidated MCR by approximately 110 basis points in the second and third quarters of 2021 and was negligible in the first quarter of 2021.
- The Medicaid MCR increased to 89.6% in the third quarter of 2021 compared to 89.0% in the second quarter of 2021. The increase in the MCR was primarily due to an increase in the net effect of COVID.
- The Medicare MCR decreased to 82.8% in the third quarter of 2021 compared to 87.6% in the second quarter of 2021. The decrease in the MCR was primarily due to the lower negative net effect of COVID among our Medicare members.
- The Marketplace MCR increased to 91.3% in the third quarter of 2021 compared to 84.8% in the second quarter of 2021. The increase in the MCR was primarily due to the higher net effect of COVID, normal seasonality, and non-COVID utilization by Special Enrollment Period members.
General and Administrative Expense Ratio
The G&A ratio for the third quarter was 7.5%, compared to 7.3% for the third quarter of 2020. The adjusted G&A ratio for the third quarter was 7.3% and was consistent with the third quarter of 2020 reflecting disciplined cost management, and growth investments.
Balance Sheet
Cash and investments at the parent company amounted to
In
Cash Flow
Operating cash flow for the nine months ended
2021 Guidance
The Company expects its full year 2021 total revenue to be no less than
Premium revenue for the full year 2021 is expected to be no less than
The Company reaffirmed its full year 2021 adjusted earnings per share guidance to be no less than
Guidance reflects:
- The continuation of the Public Health Emergency period, through mid-January, 2022 and the associated pause on Medicaid membership redeterminations;
- Underlying outperformance;
-
An offset caused by the estimated net effect of COVID which is expected to be approximately
$3.00 per share for the full year 2021; and - Continued caution in forecasting utilization trends for the remaining three months of the year due to the COVID pandemic.
The impact of the Cigna Texas membership acquisition is not included in guidance. The Cigna Texas membership acquisition is expected to close in January of 2022.
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.
Conference Call
Management is hosting a conference call and webcast to discuss Molina Healthcare’s third quarter 2021 results at
About
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements regarding its 2021 guidance, as well as its plans and expectations regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of
|
|||||||||||||||
|
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
|
|
|
|
|
|
|
|
||||||||
|
(In millions, except per-share amounts) |
||||||||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
6,800 |
|
|
$ |
4,768 |
|
|
$ |
19,689 |
|
|
$ |
13,444 |
|
Premium tax revenue |
204 |
|
|
170 |
|
|
576 |
|
|
477 |
|
||||
Health insurer fees reimbursed |
— |
|
|
69 |
|
|
— |
|
|
206 |
|
||||
Investment income |
20 |
|
|
10 |
|
|
39 |
|
|
48 |
|
||||
Other revenue |
16 |
|
|
4 |
|
|
58 |
|
|
13 |
|
||||
Total revenue |
7,040 |
|
|
5,021 |
|
|
20,362 |
|
|
14,188 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Medical care costs |
6,049 |
|
|
4,098 |
|
|
17,342 |
|
|
11,412 |
|
||||
General and administrative expenses |
532 |
|
|
368 |
|
|
1,489 |
|
|
1,030 |
|
||||
Premium tax expenses |
204 |
|
|
170 |
|
|
576 |
|
|
477 |
|
||||
Health insurer fees |
— |
|
|
70 |
|
|
— |
|
|
209 |
|
||||
Depreciation and amortization |
32 |
|
|
23 |
|
|
96 |
|
|
64 |
|
||||
Other |
2 |
|
|
3 |
|
|
30 |
|
|
9 |
|
||||
Total operating expenses |
6,819 |
|
|
4,732 |
|
|
19,533 |
|
|
13,201 |
|
||||
Operating income |
221 |
|
|
289 |
|
|
829 |
|
|
987 |
|
||||
Other expenses, net: |
|
|
|
|
|
|
|
||||||||
Interest expense |
30 |
|
|
27 |
|
|
90 |
|
|
72 |
|
||||
Other expense, net |
— |
|
|
— |
|
|
— |
|
|
5 |
|
||||
Total other expenses, net |
30 |
|
|
27 |
|
|
90 |
|
|
77 |
|
||||
Income before income tax expense |
191 |
|
|
262 |
|
|
739 |
|
|
910 |
|
||||
Income tax expense |
48 |
|
|
77 |
|
|
183 |
|
|
271 |
|
||||
Net income |
$ |
143 |
|
|
$ |
185 |
|
|
$ |
556 |
|
|
$ |
639 |
|
|
|
|
|
|
|
|
|
||||||||
Net income per share – Diluted |
$ |
2.46 |
|
|
$ |
3.10 |
|
|
$ |
9.51 |
|
|
$ |
10.65 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted average shares outstanding |
58.5 |
|
|
59.6 |
|
|
58.5 |
|
|
60.0 |
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating Statistics: |
|
|
|
|
|
|
|
||||||||
Medical care ratio |
88.9 |
% |
|
85.9 |
% |
|
88.1 |
% |
|
84.9 |
% |
||||
G&A ratio |
7.5 |
% |
|
7.3 |
% |
|
7.3 |
% |
|
7.3 |
% |
||||
Premium tax ratio |
2.9 |
% |
|
3.4 |
% |
|
2.8 |
% |
|
3.4 |
% |
||||
Effective income tax rate |
24.8 |
% |
|
29.5 |
% |
|
24.7 |
% |
|
29.8 |
% |
||||
After-tax margin |
2.0 |
% |
|
3.7 |
% |
|
2.7 |
% |
|
4.5 |
% |
|
|||||||
|
|||||||
|
|
|
|
||||
|
2021 |
|
2020 |
||||
|
Unaudited |
|
|
||||
|
(Dollars in millions, except per-share amounts) |
||||||
ASSETS |
|||||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
4,357 |
|
|
$ |
4,154 |
|
Investments |
2,900 |
|
|
1,875 |
|
||
Receivables |
1,912 |
|
|
1,672 |
|
||
Prepaid expenses and other current assets |
197 |
|
|
175 |
|
||
Total current assets |
9,366 |
|
|
7,876 |
|
||
Property, equipment, and capitalized software, net |
385 |
|
|
391 |
|
||
|
915 |
|
|
941 |
|
||
Restricted investments |
156 |
|
|
136 |
|
||
Deferred income taxes |
83 |
|
|
69 |
|
||
Other assets |
128 |
|
|
119 |
|
||
Total assets |
$ |
11,033 |
|
|
$ |
9,532 |
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||||||
Current liabilities: |
|
|
|
||||
Medical claims and benefits payable |
$ |
3,191 |
|
|
$ |
2,696 |
|
Amounts due government agencies |
2,081 |
|
|
1,253 |
|
||
Accounts payable, accrued liabilities and other |
797 |
|
|
641 |
|
||
Deferred revenue |
1 |
|
|
375 |
|
||
Total current liabilities |
6,070 |
|
|
4,965 |
|
||
Long-term debt |
2,130 |
|
|
2,127 |
|
||
Finance lease liabilities |
220 |
|
|
225 |
|
||
Other long-term liabilities |
95 |
|
|
119 |
|
||
Total liabilities |
8,515 |
|
|
7,436 |
|
||
Stockholders’ equity: |
|
|
|
||||
Common stock, |
— |
|
|
— |
|
||
Preferred stock, |
— |
|
|
— |
|
||
Additional paid-in capital |
205 |
|
|
199 |
|
||
Accumulated other comprehensive income |
17 |
|
|
37 |
|
||
Retained earnings |
2,296 |
|
|
1,860 |
|
||
Total stockholders’ equity |
2,518 |
|
|
2,096 |
|
||
Total liabilities and stockholders’ equity |
$ |
11,033 |
|
|
$ |
9,532 |
|
|
|||||||
|
|||||||
|
Nine Months Ended |
||||||
|
|
||||||
|
2021 |
|
2020 |
||||
|
|
|
|
||||
|
(in millions) |
||||||
Operating activities: |
|
|
|
||||
Net income |
$ |
556 |
|
|
$ |
639 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
96 |
|
|
64 |
|
||
Deferred income taxes |
(8 |
) |
|
(3 |
) |
||
Share-based compensation |
49 |
|
|
43 |
|
||
Loss on debt repayment |
— |
|
|
5 |
|
||
Other, net |
9 |
|
|
2 |
|
||
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables |
(247 |
) |
|
(369 |
) |
||
Prepaid expenses and other current assets |
(43 |
) |
|
(98 |
) |
||
Medical claims and benefits payable |
522 |
|
|
431 |
|
||
Amounts due government agencies |
810 |
|
|
(24 |
) |
||
Accounts payable, accrued liabilities and other |
129 |
|
|
63 |
|
||
Deferred revenue |
(374 |
) |
|
(188 |
) |
||
Income taxes |
23 |
|
|
34 |
|
||
Net cash provided by operating activities |
1,522 |
|
|
599 |
|
||
Investing activities: |
|
|
|
||||
Purchases of investments |
(2,018 |
) |
|
(670 |
) |
||
Proceeds from sales and maturities of investments |
965 |
|
|
891 |
|
||
Purchases of property, equipment, and capitalized software |
(56 |
) |
|
(64 |
) |
||
Net cash paid in business combinations |
— |
|
|
(62 |
) |
||
Other, net |
3 |
|
|
3 |
|
||
Net cash (used in) provided by investing activities |
(1,106 |
) |
|
98 |
|
||
Financing activities: |
|
|
|
||||
Common stock purchases |
(128 |
) |
|
(453 |
) |
||
Common stock withheld to settle employee tax obligations |
(52 |
) |
|
(8 |
) |
||
Contingent consideration liabilities settled |
(20 |
) |
|
— |
|
||
Proceeds from senior notes offering, net of issuance costs |
— |
|
|
789 |
|
||
Repayment of term loan facility |
— |
|
|
(600 |
) |
||
Proceeds from borrowings under term loan facility |
— |
|
|
380 |
|
||
Other, net |
(4 |
) |
|
(47 |
) |
||
Net cash (used in) provided by financing activities |
(204 |
) |
|
61 |
|
||
Net increase in cash, cash equivalents, and restricted cash and cash equivalents |
212 |
|
|
758 |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period |
4,223 |
|
|
2,508 |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at end of period |
$ |
4,435 |
|
|
$ |
3,266 |
|
|
||||||||
|
||||||||
|
|
|
|
|
|
|||
|
2021 (1) |
|
2020 |
|
2020 |
|||
Ending Membership by Segment: |
|
|
|
|
|
|||
Medicaid |
3,981,000 |
|
|
3,599,000 |
|
|
3,595,000 |
|
Medicare |
138,000 |
|
|
115,000 |
|
|
113,000 |
|
Marketplace |
719,000 |
|
|
318,000 |
|
|
325,000 |
|
Total |
4,838,000 |
|
|
4,032,000 |
|
|
4,033,000 |
|
|
|
|
|
|
|
|||
______________________________
|
|
Three Months Ended |
||||||||||||||||||||
|
2021 |
|
2020 |
||||||||||||||||||
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicaid |
$ |
5,034 |
|
|
$ |
551 |
|
|
89.0 |
% |
|
$ |
3,375 |
|
|
$ |
553 |
|
|
83.6 |
% |
Medicare |
814 |
|
|
101 |
|
|
87.6 |
|
|
630 |
|
|
125 |
|
|
80.0 |
|
||||
Marketplace |
735 |
|
|
112 |
|
|
84.8 |
|
|
367 |
|
|
96 |
|
|
74.0 |
|
||||
Consolidated |
$ |
6,583 |
|
|
$ |
764 |
|
|
88.4 |
% |
|
$ |
4,372 |
|
|
$ |
774 |
|
|
82.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Three Months Ended |
||||||||||||||||||||
|
2021 |
|
2020 |
||||||||||||||||||
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicaid |
$ |
5,146 |
|
|
$ |
532 |
|
|
89.6 |
% |
|
$ |
3,754 |
|
|
$ |
509 |
|
|
86.4 |
% |
Medicare |
875 |
|
|
151 |
|
|
82.8 |
|
|
632 |
|
|
91 |
|
|
85.6 |
|
||||
Marketplace |
779 |
|
|
68 |
|
|
91.3 |
|
|
382 |
|
|
70 |
|
|
81.6 |
|
||||
Consolidated |
$ |
6,800 |
|
|
$ |
751 |
|
|
88.9 |
% |
|
$ |
4,768 |
|
|
$ |
670 |
|
|
85.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Nine Months Ended |
||||||||||||||||||||
|
2021 |
|
2020 |
||||||||||||||||||
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicaid |
$ |
15,020 |
|
|
$ |
1,687 |
|
|
88.8 |
% |
|
$ |
10,415 |
|
|
$ |
1,427 |
|
|
86.3 |
% |
Medicare |
2,488 |
|
|
329 |
|
|
86.8 |
|
|
1,896 |
|
|
333 |
|
|
82.4 |
|
||||
Marketplace |
2,181 |
|
|
331 |
|
|
84.8 |
|
|
1,133 |
|
|
272 |
|
|
76.0 |
|
||||
Consolidated |
$ |
19,689 |
|
|
$ |
2,347 |
|
|
88.1 |
% |
|
$ |
13,444 |
|
|
$ |
2,032 |
|
|
84.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
______________________________
|
|||||||||||||||||||||
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
|
Nine Months Ended |
||||||
|
|
||||||
|
2021 |
|
2020 |
||||
|
|
|
|
||||
|
Unaudited |
||||||
Medical claims and benefits payable, beginning balance |
$ |
2,696 |
|
|
$ |
1,854 |
|
Components of medical care costs related to: |
|
|
|
||||
Current year |
17,558 |
|
|
11,478 |
|
||
Prior year |
(216 |
) |
|
(66 |
) |
||
Total medical care costs |
17,342 |
|
|
11,412 |
|
||
Payments for medical care costs related to: |
|
|
|
||||
Current year |
14,880 |
|
|
9,500 |
|
||
Prior year |
2,008 |
|
|
1,527 |
|
||
Total paid |
16,888 |
|
|
11,027 |
|
||
Change in acquired balances |
(27 |
) |
|
— |
|
||
Change in non-risk and other provider payables |
68 |
|
|
50 |
|
||
Medical claims and benefits payable, ending balance |
$ |
3,191 |
|
|
$ |
2,289 |
|
|
|
|
|
||||
Days in claims payable, fee for service (1) |
49 |
|
|
52 |
|
||
______________________________
|
|||||||
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted after-tax margin represents adjusted net income, divided by total revenue.
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||||||||||||||
2021 |
|
2020 |
|
2021 |
|
2020 |
|||||||||||||||||||||||||
|
Amount |
|
Per Diluted Share |
|
Amount |
|
Per Diluted Share |
|
Amount |
|
Per Diluted Share |
|
Amount |
|
Per Diluted Share |
||||||||||||||||
Net income |
$ |
143 |
|
|
$ |
2.46 |
|
|
$ |
185 |
|
|
$ |
3.10 |
|
|
$ |
556 |
|
|
$ |
9.51 |
|
|
$ |
639 |
|
|
$ |
10.65 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Acquisition-related expenses (1) |
17 |
|
|
0.28 |
|
|
4 |
|
|
0.07 |
|
|
44 |
|
|
0.75 |
|
|
4 |
|
|
0.06 |
|
||||||||
Amortization of intangible assets |
11 |
|
|
0.20 |
|
|
4 |
|
|
0.06 |
|
|
35 |
|
|
0.60 |
|
|
12 |
|
|
0.19 |
|
||||||||
Loss on debt repayment |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
5 |
|
|
0.08 |
|
||||||||
Other (2) |
— |
|
|
— |
|
|
13 |
|
|
0.21 |
|
|
9 |
|
|
0.16 |
|
|
19 |
|
|
0.32 |
|
||||||||
Subtotal, adjustments |
28 |
|
|
0.48 |
|
|
21 |
|
|
0.34 |
|
|
88 |
|
|
1.51 |
|
|
40 |
|
|
0.65 |
|
||||||||
Income tax effect |
(7 |
) |
|
(0.11 |
) |
|
(5 |
) |
|
(0.08 |
) |
|
(21 |
) |
|
(0.36 |
) |
|
(9 |
) |
|
(0.15 |
) |
||||||||
Adjustments, net of tax |
21 |
|
|
0.37 |
|
|
16 |
|
|
0.26 |
|
|
67 |
|
|
1.15 |
|
|
31 |
|
|
0.50 |
|
||||||||
Adjusted net income |
$ |
164 |
|
|
$ |
2.83 |
|
|
$ |
201 |
|
|
$ |
3.36 |
|
|
$ |
623 |
|
|
$ |
10.66 |
|
|
$ |
670 |
|
|
$ |
11.15 |
|
|
|||||||||||||||||||||||||||||||
______________________________
|
|||||||||||||||||||||||||||||||
(2) The nine months ended |
|
|||
Net income per diluted share (1) |
$ |
11.61 |
|
Adjustments: |
|
||
Acquisition-related expenses |
1.18 |
|
|
Amortization of intangible assets |
0.81 |
|
|
Other |
0.16 |
|
|
Subtotal, adjustments |
2.15 |
|
|
Income tax effect (2) |
(0.51 |
) |
|
Adjustments, net of tax |
1.64 |
|
|
Adjusted net income per diluted share |
$ |
13.25 |
|
|
|||
______________________________
|
|||
(2) Income tax effect calculated at the statutory tax rate of 23.8%. |
|||
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027006069/en/
Investor Contact:
Media Contact:
Source: